Home/Pipeline/FGF18 Gene Therapy

FGF18 Gene Therapy

Osteoarthritis

Pre-clinicalActive

Key Facts

Indication

Osteoarthritis

Phase

Pre-clinical

Status

Active

Company

Remedium Bio

About Remedium Bio

Remedium Bio is a private, pre-clinical stage biotech leveraging its proprietary Prometheus™ platform to create single-injection, adjustable-dose gene therapies. The platform aims to replace chronic subcutaneous biologic treatments across multiple therapeutic areas, including obesity/type 2 diabetes, stroke, and osteoarthritis. While promising, the company faces significant risks typical of early-stage gene therapy developers, including platform validation, clinical translation, and intense competition. Its success hinges on demonstrating proof-of-concept for its novel adjustable delivery system in human trials.

View full company profile

Therapeutic Areas

Endocrinology Neurology Rheumatology Immunology Musculoskeletal

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
MSC‑OA	Advancells	Phase 1	Active
Osteoarthritis program	Risen Pharma Tech	Clinical (China & US)	Active
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
PKM-011	PK MED	Pre-clinical	Active
CYT-108	Cytonics	Phase 2	Active
Topical PSGAG	ADORA Life Science	Pre-clinical	Active
MOTYS™	Doron Therapeutics	Phase 3	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
aGF	Scarcell Therapeutics	Phase 1	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
BRM521	BRIM Biotechnology	Preclinical	Active